UK industry agrees flexible five-year price plan after cuts – update
This article was originally published in Scrip
Executive Summary
The UK pharmaceutical industry and the government have reached agreement on a new five-year pharmaceutical price regulation scheme (PPRS) that revises rather than rewrites the system that has governed drug pricing in the UK for 50 years. When the government announced last year that it was scrapping the PPRS, many in industry feared a radical overhaul, but the version mostly finalised this week retains the principal elements of the original scheme.
You may also be interested in...
Cervarix link to UK girl's death "unlikely"
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Generic Topamax launched in European markets
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
NICE confirms limits on Alimta for lung cancer
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.